Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 231-272-0 | CAS number: 7473-98-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
Additional information
Chemistry
The test material (164 Da) is a yellowish liquid, well soluble in water (13.3 g/l). The material has a density of 1.08 g/cm3 and the boiling point is at 252 °C. A vapour pressure of 0.0057 hPa indicates a very low volatility. The log Pow is 1.62 (at pH 5.75).
The substance is sensitive to UV-light induced photocleavage as it was designed to serve the technical function of a photoinitiator.
Absorption
In acute oral and dermal toxicity studies, rats were administered to the test substance. Mortality was observed in all treatment groups after oral administration (with exception of the lowest dose level) in a dose dependent manner. A few minutes after oral application animals showed sedation, dyspnoe, decreased activity and proned position. In animals which died fatty liver infiltration and dilation of the bladder (starting at 1800 mg/kg) as well as mucous content of the intestine (starting at 2000 mg/kg) was observed. Single dermal application resulted in mortality from 5000 mg/kg bw onward. Gross pathology of deceased animals revealed fatty infiltration of the liver and dilation of the urinary bladder with hemorrhaging of the mucosa (starting at 6400 mg/kg). Furthermore, staggered gait and decreased activity were observed. The NOAEL in male and female rats in a subacute oral repeated dose study is 300 mg/kg bw due to changes in liver and kidney weight as well as centrilobular hypertrophy and hepatocellular proliferation. Administration of the substance over a subchronic period resulted in gait ataxia in high dose males. Furthermore, basophillic tubules and granular cast in the kidneys were observed. Calcium oxalate and crystals were found in the urine of the top dose animals. The NOAEL after subchronic oral administration is therefore considered to be 50 mg/kg bw. In regard to the results of the acute and longterm studies and considering the low molecular weight uptake of the substance from the gastro-intestinal system is most likely. The test substance cannot undergo pH-dependent hydrolysis in the stomach, thus, the unchanged (parent) substance is taken up into the system. According to the model of Fitzpatrick [1], the test item is moderately skin permeable.
Metabolism
The results obtained from the subchronic toxicity study indicate the test item forms a complex with Ca2+ (2:1). A subsequent decrease of systemic calcium may cause mobilisation of calcium from the bones which results in turn in increased Ca-levels (as observed in the 90d study). Additionally, the Ca-complexes are presumably precipitated in kidney and urine.
Concerning xenobiotic metabolism, reduction of the aliphatic ketone followed by glucuronidation of the hydroxyl-groups seems plausible. Subsequently, the test substance will be excreted effectively. The primary elimination pathway of the test substance will be the urinary excretion of parent compound and the glucuronidation product.
Excretion
The low molecular weight of the test item and its solubility in water enhance renal excretion. However, precipitation of the Ca-bound complex and crystal formation in kidney and urine was observed at the highest dose level when applied over a subchronic period. It is acceptable to assume that the precipitated material will be excreted over the time after discontinuation of administration. Accumulation in the body is therefore not expected.
[1] Modelling skin permeability in risk assessment––the future, D. Fitzpatrick et al, Chemosphere 55 (2004) 1309–1314
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.